| Literature DB >> 32200776 |
Matthew P Marggraf1, Paul H Lysaker2, Michelle P Salyers1, Kyle S Minor1.
Abstract
BACKGROUND: Formal thought disorder (FTD) and social functioning impairments are core symptoms of schizophrenia. Although both have been observed for over a century, the strength of the relationship between FTD and social functioning remains unclear. Furthermore, a variety of methodological approaches have been used to assess these constructs-which may contribute to inconsistency in reported associations. This meta-analysis aimed to: (a) systematically test the relationship between FTD and social functioning and (b) determine if the methodology used to assess FTD and/or social functioning moderates this relationship.Entities:
Keywords: Disorganized; meta-analysis; schizophrenia; social functioning; thought disorder
Mesh:
Year: 2020 PMID: 32200776 PMCID: PMC7355127 DOI: 10.1192/j.eurpsy.2020.30
Source DB: PubMed Journal: Eur Psychiatry ISSN: 0924-9338 Impact factor: 5.361
Figure 1.PRISMA study retrieval flow diagram.
Overview of sample characteristics.
| Sample characteristics | Mean (SD) | Range |
|
|---|---|---|---|
| Mean age | 41.0 (7.1) | 30.74–56.01 | 12 |
| Percent female | 34.3 (9.2) | 24.5–48.6 | 13 |
| Percent Caucasian | 56.9 (23.7) | 33.5–95.0 | 9 |
| Percent African-American | 31.6 (23.6) | 3.8–66.0 | 8 |
| Percent diagnosis | |||
| Schizophrenia | 84.1 (18.7) | 57.0–100.0 | 10 |
| Schizoaffective | 13.7 (16.2) | 0–43.0 | 10 |
| Other psychosis | 1.3 (4.8) | 0–17.5 | 13 |
| Mean total symptoms | 2.18 (0.21) | 1.93–2.40 | 7 |
| Mean positive symptoms | 2.37 (0.31) | 1.96–2.75 | 9 |
| Mean negative symptoms | 2.16 (0.45) | 1.46–3.00 | 9 |
| Sample type ( | |||
| Peer-reviewed | 10 (76.9%) | – | 13 |
| Dissertation | 2 (15.4%) | 13 | |
| Other | 1 (7.7%) | 13 | |
| Mean year | 2010 (6.4) | 1999–2017 | 13 |
| Mean sample size (total | 113.7 | 40–345 | 13 |
| Location ( | |||
| North America | 8 (61.5%) | – | 13 |
| Asia | 3 (23.1%) | – | 13 |
| Australia | 1 (7.7%) | 13 | |
| Europe | 1 (7.7%) | 13 | |
Abbreviations: Mean total, positive, and negative symptoms, average single item scores on PANSS equivalent symptom rating measure; SD, standard deviation.
Study-level descriptive statistics for included studies.
| Author | Country |
| %Fem. | %SCZ/SZA | %Cauc. | Mean age | Mean symps. | FTD measure | Social Fx measure | Association type |
| ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tot | Pos | Neg | |||||||||||
| Bowie et al. [ | Canada | 90 | 24.5 | 100 | 54.4 | – | – | 2.60 | 2.66 | TLC | SDS | CR-SR | −0.110 |
| TLC | SLOF-Soc | CR-CR | −0.180 | ||||||||||
| TLC | SSPA | CR-PB | −0.350 | ||||||||||
| De Sousa et al. [ | England | 80 | 27.5 | 82.5 | 95.0 | 39.3 | 2.33 | 2.40 | 2.00 | TLC | LSNS | CR-SR | −0.541 |
| PANSS | LSNS | CR-SR | −0.572 | ||||||||||
| Gilbert [ | United States | 40 | 30.0 | 100 | 40 | 35.6 | 2.30 | – | – | BPRS: Global FTD | GF: Social | CR-CR | −0.300 |
| SAPS: FTD | GF: Social | CR-CR | −0.350 | ||||||||||
| TDI | GF: Social | BB-CR | −0.120 | ||||||||||
| Luther, Lysaker, and Lysaker [57–59] | United States | 345 | 25 | 95 | 33.5 | 45.8 | – | 2.69 | 2.27 | PANSS | QOL:Inter | CR-CR | −0.001 |
| Moore et al. [ | United States | 72 | 49 | 100 | 43 | 51.2 | 2.01 | 1.99 | 2.16 | EII | SSPA | BB-PB | −0.004 |
| Muralidharan et al. [ | United States | 248 | 26 | 100 | 52.2 | 56.0 | – | 1.96 | 1.98 | TLC | SLOF-Soc | CR-CR | −0.216 |
| TLC | SSPA | CR-PB | −0.139 | ||||||||||
| TLC | UPSA-Com | CR-PB | −0.282 | ||||||||||
| Nienow [ | United States | 56 | 25 | 100 | 34 | 41.5 | 2.40 | 2.49 | 1.46 | BPRS | AIPSS | CR-PB | −0.220 |
| Racenstein et al. [ | United States | 59 | 34 | 100 | 66 | 30.74 | – | – | – | IPTD-Comp | SCOS-SF | BB-CR | 0.100 |
| IPTD-Prov | SCOS-SF | BB-CR | −0.190 | ||||||||||
| IPTD-Obj | SCOS-SF | BB-CR | −0.170 | ||||||||||
| Smith et al. [ | United States | 46 | 37 | 100 | 94 | 39 | – | – | – | SAPS:FTD | QOLI-Int | CR-CR | −0.530 |
| Suttajit et al. [ | Thailand | 199 | 47.7 | 100 | – | 37.95 | 1.93 | 2.75 | 1.90 | PANSS: | PSP | CR-CR | −0.424 |
| Tan et al. [ | Australia | 54 | 48.1 | 100 | – | 43.35 | – | 2.01 | 2.01 | PANSS | QOLI:Soc-sbj | CR-SR | −0.090 |
| PANSS | QOLI:Fam-sbj | CR-SR | 0.100 | ||||||||||
| PANSS | QOLI:Soc-obj | CR-CR | 0.030 | ||||||||||
| PANSS | QOLI:Fam-obj | CR-CR | 0.040 | ||||||||||
| Ulas et al. [ | Turkey | 72 | 39 | 100 | – | 35.7 | 1.94 | – | – | TLI-DT | WHOQOL-Soc | BB-CR | −0.182 |
| Yalincetin et al. [ | Turkey | 117 | 34 | 100 | – | 36.02 | 2.38 | 2.42 | 3.00 | TLI-DT | PSP | BB-CR | −0.230 |
Abbreviations: AIPSS, Assessment of Interpersonal Problem Solving Skills; Association type: first abbreviation corresponds to type of FTD measure—BB, behaviorally based; CR, clinician rated; second abbreviation corresponds to type of social functioning measure—CR, clinician rated; PB, performance-based; SR, self-report; BPRS, Global FTD item on the Brief Psychiatric Rating Scale; %Cauc., % of sample that is Caucasian; EII, Ego Impairment Index; Fam-obj, Objective rating on Family item on QOLI; %Fem, % of sample that is female; FTD Meas, name of measure(s) used to assess FTD; GF: Social, Global Functioning: Social Scale; IPTD, Index of Positive Thought Disorder—Comp, Comprehension Subtest—Prov, Proverb Subtest—Obj, Object Sorting Subtest; LSNS, Lubben Social Network Scale; Mean symps., mean symptom; N, number of participants included in the study; Neg, mean for negative symptom item; PANSS, Conceptual Disorganization Item on the Positive and Negative Syndrome Scale; Pos, mean for positive symptom item; PSP, Personal and Social Performance Scale; QOL:Inter, Interpersonal Subscale of Quality of Life Scale; QOLI: Fam-subj, Subjective rating for Family item on QOLI; QOLI-Inter, Interpersonal domain on the Quality of Life Interview; QOLI: Soc-subj, Subjective rating for Social item on the Quality of Life Interview; SAPS-FTD, Global item for the FTD subscale of the Scale for the Assessment of Positive Symptoms; SCOS-SF, Strauss Carpenter Outcomes Scale—Social Functioning subscale; %SCZ/SZA, % of sample with schizophrenia or schizoaffective diagnosis; SDS, Sheehan Disability Scale—Social subscale; SLOF-Soc, Specific Level of Functioning Scale—Social Functioning; Soc-sbj, Subjective rating for Social item on QOLI; Soc-obj, Objective rating for Social item on QOLI; Social Fx, name of measure(s) used to assess social functioning; SSPA, Social Skill Performance Assessment; TDI, Thought Disorder Index; TLC, Thought, Language, and Communication Scale; TLI-DT Thought and Language Index—Disorganized Thinking subscale; Tot, mean total symptom item; UPSA-Comm, Communication subtest of the University of California-San Diego Performance-Based Skills Assessment: WHOQOL-Soc, World Health Organization Quality of Life Scale—Social Domain.
Figure 2.Forest plot of studies included in the meta-analysis examining the relationship between FTD and social functioning (k = 13).
Summary of mean effect size for the association between FTD and social functioning.
|
| ES— | 95% CI |
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|
| FTD—social functioning | 13 | –0.23 | [–0.33, –0.12] | –3.92 | <0.001 | 52.77 | <0.001 | 77.26 |
Abbreviations: 95% CI, 95% confidence interval for the mean effect size; ES, sample weighted averaged observed correlation; FTD, formal thought disorder; I 2, the extent of between-study variability; k, number of studies used in the calculation of the mean effect size; Q, test for presence of heterogeneity; Z, z-test for statistical significance of the mean effect size.
Categorical and continuous moderator analyses.
| Categorical moderator |
| ES— | 95% CI |
|
|
|
| |
|---|---|---|---|---|---|---|---|---|
| FTD measure | 14 | −0.23 | [−0.33, −0.12] | −3.99 | <0.001 | 1.90, 1 (0.168) | 75.77 | |
| Clinician-rated | 9 | −0.28 | [−0.40, −0.14] | −3.97 | <0.001 | 83.73 | ||
| Behaviorally based | 5 | −0.13 | [−0.31, 0.07] | −1.31 | 0.192 | 0.00 | ||
| Social function measure | 17 | −0.21 | [−0.30, −0.12] | −4.34 | <0.001 | 1.15, 2 (0.563) | 72.63 | |
| Self-report | 3 | −0.25 | [−0.46, −0.02] | −2.10 | 0.035 | 87.47 | ||
| Clinician-rated | 10 | −0.21 | [−0.33, −0.08] | −3.27 | 0.001 | 75.20 | ||
| Performance-based | 4 | −0.20 | [−0.38, −0.01] | −1.98 | 0.048 | 40.67 | ||
| Study quality | 13 | −0.23 | [−0.33, −0.12] | −3.88 | <0.001 | 3.35, 1 (0.067) | 77.25 | |
| High | 6 | −0.28 | [−0.44, −0.11] | −3.16 | 0.002 | 76.44 | ||
| Moderate | 7 | −0.19 | [−0.33, −0.04] | −2.40 | 0.016 | 78.72 | ||
| Continuous moderator |
|
|
| SE | 95% CI |
|
|
|
| %Female | 12 | −0.21 | 0.03 | 0.72 | [−1.62, 1.20] | −0.29 | 0.77 | 78.03 |
| Age | 11 | 0.01 | 0.00 | 0.09 | [−0.01, 0.03] | 0.84 | 0.40 | 80.02 |
| Total symptoms | 7 | −0.01 | 0.00 | 0.01 | [−0.03, 0.02] | −0.34 | 0.74 | 70.84 |
| Positive symptoms | 9 | −0.26 | 0.00 | 0.27 | [−0.79, 0.27] | −0.95 | 0.34 | 82.42 |
| Negative symptoms | 9 | 0.07 | 0.00 | 0.18 | [−0.28, 0.42] | 0.42 | 0.68 | 82.42 |
The p-value of Q bet indicates whether the subgroups are significantly different.
Abbreviations: B, regression coefficient; CI, confidence interval; ES, r effect size statistic; I, extent of between-study variability; k, number of studies used in the calculation of the mean effect size; p, two-tailed p-value associated with the test of statistical significance; Q bet, variance between subgroups; R, R analogue; SE, standard error, z, test for statistical significance of the mean effect size.
For this analysis, one study [98] contributed effect sizes to both clinician-rated and behaviorally-based subgroups.
For this analysis three studies contributed multiple effect sizes.
The I 2 value might be larger than that of the overall main analyses because not all of the studies were included in the moderator analyses.